Condition
Covert Hepatic Encephalopathy
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Unknown1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07046429Not ApplicableRecruiting
Affect of Melatonin on Sleep and Cognition in Cirrhosis
NCT06367127Unknown
Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
NCT05189834Not ApplicableWithdrawnPrimary
GELSECTAN® and Covert Hepatic Encephalopathy
NCT03585257Phase 2Completed
HEAL STUDY (Hepatic Encephalopathy and Albumin Study)
NCT03077217Phase 4CompletedPrimary
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
Showing all 5 trials